Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 71Lung Neoplasms 32Triple Negative Breast Neoplasms 23Breast Neoplasms 19Small Cell Lung Carcinoma 15Ovarian Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Endometrial Neoplasms 13Neoplasms 12Parkinson Disease 4, Autosomal Dominant Lewy Body 10Fallopian Tube Neoplasms 10Neoplasm Metastasis 9Colorectal Neoplasms 6Urinary Bladder Neoplasms 5Carcinoma 5Adenocarcinoma of Lung 5Esophageal Neoplasms 4Uterine Cervical Neoplasms 3Pathologic Complete Response 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Mesothelioma 3Melanoma 3Lung Diseases 3Head and Neck Neoplasms 3Esophageal Squamous Cell Carcinoma 3Central Nervous System Neoplasms 3Uterine Neoplasms 2Thoracic Neoplasms 2Sarcoma 2

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Carboplatin × 30 days × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡